ImmunoMet Therapeutics, Inc. announced that it has received $5.000004 million in funding from Incon Co., Ltd. and other investors
February 05, 2020
Share
ImmunoMet Therapeutics, Inc. announced a private placement of 608,273 shares at a price of $8.22 per share led by returning investor, Incon Co., Ltd. (KOSDAQ:A083640) for gross proceeds of $5,000,004 on February 5, 2020. The transaction also includes participation from other new investors. Incon Co., Ltd. (KOSDAQ:A083640) participated for 289,117 shares and acquired 3.73% stake in the transaction and holds 21.59% stake in the company. The transaction has been approved by the board of directors of the investor.
INCON Co., Ltd., formerly Win4Net Co., Ltd. is a Korea-based company specialized in the development and manufacture of digital video recorders (DVRs) used for security area. The Companyâs products consist of standalone DVRs, personal computer (PC)-based DVRs, analog cameras, color box cameras, indoor dome cameras, outdoor micro dome cameras, outdoor dome cameras and others. Its Internet protocol (IP) products include network video recorders (NVRs), video servers, hybrid DVRs, IP cameras and related software. It also provides storages. It distributes its products under the brand names of Netsafe, Trium, Poswatch, Clevo, Netsafe, Wintera and others. The Company distributes its products within domestic market and to overseas markets.
INCON CO.,LTD. 
